drugset / Trial / NCT01364974

A Study to Assess the Safety, Tolerability and Pharmacokinetics of ASP015K

NCT01364974

Phase 1 Completed 48 enrolled Astellas Pharma Inc
RandomizedParallel-groupQuadruple-blind

Summary

The objective of this study is to explore safety and tolerability of multiple oral doses of ASP015K in healthy volunteers.

Timeline

Start
2009-01
Primary completion
2009-05
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject peficitinib Small molecule Oral

Indications

No indication recorded.